The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
We talk to Giffin Daughtridge, CEO of medical diagnostics company, UrSure, about treatment adherence and the impact of long-acting cabotegravir as injectable PrEP.
The 23rd International AIDS Conference (AIDS 2020 Virtual) kicked-off with a clear message from UNAIDS to accelerate efforts to end AIDS and not be derailed by COVID-19.
Peer distribution, youth branding and social media campaigns emerge as top ideas in crowdsourcing contest to improve HIV self-testing among young people.
World Health Organization changes its position on the wearing of non-medical fabric face masks.
Long-acting, injectable cabotegravir is as effective as daily PrEP pills at preventing HIV among cisgender men and transgender women who have sex with men.
If you’re living with HIV and wondering how the new coronavirus may affect you, here are some tips to help you look after yourself.
Modelling finds PrEP has the potential to avert between 3 and 8% of HIV infections in 13 African and Caribbean countries by 2030 if three key populations can access it
Viral load testing trial finds 49% are virally unsuppressed while one in five are failing their treatment with suspected drug resistance.
Research on PrEP safety for pregnant women and their babies finds no adverse effects – but knowledge gaps remain.
Study with transgender women suggests taking on-demand PrEP with hormone therapy may result in drug levels too low for HIV prevention.
